Shares of Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus price target of $10.00 for the company and are predicting that the company will post ($0.01) EPS for the current quarter, according to Zacks. Zacks has also given Kitov Pharmaceuticals an industry rank of 158 out of 265 based on the ratings given to its competitors.

Separately, HC Wainwright raised Kitov Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Tuesday, November 21st.

Shares of Kitov Pharmaceuticals (NASDAQ:KTOV) traded up $0.15 during mid-day trading on Friday, reaching $2.46. The company had a trading volume of 424,574 shares, compared to its average volume of 200,575. Kitov Pharmaceuticals has a 52-week low of $1.27 and a 52-week high of $3.49.

COPYRIGHT VIOLATION WARNING: This story was first posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at

Kitov Pharmaceuticals Company Profile

Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Get a free copy of the Zacks research report on Kitov Pharmaceuticals (KTOV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Kitov Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals and related companies with's FREE daily email newsletter.